CureVac in the Media

  • Handelsblatt: "So sieht Bill Gates die Zukunft der Menschheit"
    18-11-09 / Media Report
    Read more
  • Fortune:"Bill Gates Just Delivered a Powerful Message to the Drug Industry"
    18-01-09 / Media Report
    Read more
  • Endpoints News: "Eli Lilly is making a $1.8B leap into the mRNA field, targeting next-gen cancer vaccines"
    17-10-20 / Media Report
    Read more
  • FierceBiotech: "Lilly, CureVac pen $1.8B mRNA cancer vaccine deal"
    17-10-18 / Media Report
    Read more
  • Financial Times: "Eli Lilly invests in Germany’s CureVac in cancer vaccine drive"
    17-10-18 / Media Report
    Read more
  • Nature Biotechnology: "A successful founder off the beaten path"
    17-10-12 / Media Report
    Read more
  • BIOspektrum: "Molekulare Medizin - mRNA-basierte Therapien für eine passive Immunisierung"
    17-09-11 / Media Report
    Read more
  • Handelsblatt Global: "Vaccine research - Rabid about Curevac"
    17-07-27 / Media Report
    Read more
  • Handelsblatt Global: "Top Innovators - Germany's Quiet Visionaries, Part X"
    17-03-17 / Media Report
    Read more
  • Nature Biotechnology: "The 'anti-hype' vaccine"
    17-02-27 / Media Report
    Read more
  • BioCentury: "mRNA test kitchens - Where biopharma is betting on mRNA"
    17-02-25 / Media Report
    Read more
  • European Biotechnology: "Biotech CEOs advise EU on breakthrough innovations"
    17-01-23 / Media Report
    Read more
  • Handelsblatt Global Edition: "Bill Gates: We Need To Be Prepared For Epidemics"
    17-01-19 / Media Report
    Read more
  • idw - Informationsdienst Wissenschaft (German): "Bill Gates: We Need To Be Prepared For Epidemics"
    17-01-17 / Media Report
    Read more
  • GEN (Genetic Engineering & Biotechnology News): "Enabling the Body to Manufacture Its Own Medicine"
    16-11-02 / Media Report
    Read more
  • Deutsches Ärzteblatt (German): "HIV-Impfung: Nicht in Sicht, aber in Arbeit"
    16-08-08 / Media Report
    Read more
  • The Wall Street Journal: "Ebola, Zika Push Global Health Leaders on Disease Fight, Bill & Melinda Gates Foundation CEO Says"
    16-05-23 / Media Report
    Read more
  • Handelsblatt (German): "Deutschland braucht mehr Erfolgsstorys"
    16-04-13 / Media Report
    Read more
  • Süddeutsche Zeitung (German): "Das Geschäft machen andere"
    16-04-13 / Media Report
    Read more
  • Stuttgarter Zeitung (German): "Deutsche Biotech-Branche schöpft Potenzial nicht aus"
    16-04-12 / Media Report
    Read more
  • DER SPIEGEL (German): "Einhorn aus Tübingen - Curevac gilt als größte Hoffnung der deutschen Biotech-Szene..."
    16-03-26 / Media Report
    Read more
  • LaBiotech: "Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?"
    16-01-05 / Media Report
    Read more
  • Handelsblatt (German): "Es geht uns nicht ums Geldverdienen"
    15-12-16 / Media Report
    Read more
  • Frankfurter Allgemeine Zeitung (German): "Nur mal schnell die Welt retten"
    15-12-13 / Media Report
    Read more
  • Rhein-Neckar-Zeitung (German): "Mannheim: Roche offen für Partnerschaften"
    15-11-13 / Media Report
    Read more
  • Handelsblatt (German): "Curevac erhält Finanzspritze - 100 Millionen Euro für den Biotech-Star"
    15-11-03 / Media Report
    Read more
  • DowJones VENTUREWIRE: "CureVac Amasses $110M for Messenger RNA Therapeutics"
    15-11-03 / Media Report
    Read more
  • FierceBiotech: "Gates, Hopp back $110M megaround for CureVac's mRNA work"
    15-11-02 / Media Report
    Read more
  • Xconomy: "CureVac Opens up an mRNA Hub in Moderna’s Cambridge Backyard"
    15-09-10 / Media Report
    Read more
  • Süddeutsche Zeitung (German): "Pioniere der Biotechnologie"
    15-09-02 / Media Report
    Read more
  • Frankfurter Allgemeine Sonntagszeitung / faz.net (German): "Milliarden für ein Molekül"
    15-08-30 / Media Report
    Read more
  • BIOPRO (German): "CureVac und Boehringer Ingelheim - zwei starke Partner im Kampf gegen Krebs"
    15-07-13 / Media Report
    Read more

Your contact

Matthew Beck
Vice President Investor Relations
T: +1 917 415 1750
contact via e-mail